Skip to main content
SpringerLink
Log in

Langzeitremission bei malignem Melanom Stadium IV nach antigenspezifischer Immuntherapie

Long-Term Remission of Malignant Melanoma Stage IV after Antigen-Specific Immunotherapy

  • KASUISTIK
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

Zusammenfassung

Die vorliegende Kasuistik stellt eine Patientin mit malignem Melanom Stadium IV (M1a) vor, bei der nach Progress unter der Standardchemotherapie durch eine experimentelle, spezifische Tumorvakzinierung eine partielle Remission der Erkrankung erzielt wurde. Der Langzeiterfolg dieser Behandlung von über 15 Jahren wird auf eine nachweisbare spezifische Immunantwort auf die Vakzinierung zurückgeführt.

Abstract

This case report describes the clinical course of a patient with progressing metastatic melanoma (M1a) under standard chemotherapy, followed by long-term partial remission of disease under treatment with experimental, specific immunotherapy. Detectable specific immune responses demonstrate the correlation between continued tumor regression and the administered specific immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Jäger E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67:54–62.

    Article  PubMed  Google Scholar 

  2. Jäger E, Karbach J, Gnjatic S, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 2006;103:14453–8.

    Article  PubMed  Google Scholar 

  3. Jäger E, Maeurer M, Höhn H, et al. Clonal expansion of melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000;86:538–47.

    Article  PubMed  Google Scholar 

  4. Boon T, Van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725–9.

    Article  CAS  PubMed  Google Scholar 

  5. Caballero OL, Chen Y T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100:2014–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt/Main, Germany

    Antje Neumann, Julia Karbach, Akin Atmaca &  Elke Jäger

  2. Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Steinbacher Hohl 2–26, 60488, Frankfurt, Germany

    Elke Jäger

Authors
  1. Antje Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Karbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akin Atmaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elke Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elke Jäger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neumann, A., Karbach, J., Atmaca, A. et al. Langzeitremission bei malignem Melanom Stadium IV nach antigenspezifischer Immuntherapie. Med Klin 105, 273–275 (2010). https://doi.org/10.1007/s00063-010-1041-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-010-1041-7

Schlüsselwörter:

Key Words:

Search

Navigation